Vasopressin Excess and Hyponatremia

American Journal of Kidney Diseases

Volumn 47, Issue 5, 2006, Pages 727-737

  Pham, Phuong Chi T ^a,b,c   Pham, Phuong Mai T ^a,b,c   Pham, Phuong Thu T ^a,b,c  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTRAL MAINE MEDICAL CENTER   (United States)

Author keywords

arginine vasopressin receptor antagonist; cirrhosis; congestive heart failure; Hyponatremia; syndrome of inappropriate secretion of antidiuretic hormone

Indexed keywords

ARGIPRESSIN; CONIVAPTAN; LIXIVAPTAN; LOOP DIURETIC AGENT; SODIUM; SODIUM CHLORIDE; TOLVAPTAN; VASOPRESSIN; WATER;

ARTICLE; CLINICAL TRIAL; DIURESIS; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; HUMAN; HYPONATREMIA; SODIUM BLOOD LEVEL; WATER DEPRIVATION; WATER RETENTION;

ARGININE VASOPRESSIN; AZEPINES; BENZAMIDES; BENZAZEPINES; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN; WATER-ELECTROLYTE BALANCE;

EID: 33646042193     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.01.020     Document Type: Article

References (55)

1. Adrogué H.J., and Madias N.E. Hyponatremia. N Engl J Med 342 (2000) 1581-1589
2. Saeed B.O., Beaumont D., Handley G.H., and Weaver J.U. Severe hyponatraemia. Investigation and management in a district general hospital. J Clin Pathol 55 (2002) 893-896
3. Gill G., and Leese G. Hyponatremia. Biochemical and clinical perspectives. Postgrad Med J 74 (1998) 516-523
4. Tierney W.M., Martin D.K., Greenlee M.C., Zerbe R.L., and McDonald C.J. The prognosis of hyponatremia at hospital admission. J Gen Intern Med 1 (1986) 380-385
5. Anderson R.J., Chung H.M., Kluge R., and Schrier R.W. Hyponatremia. A prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 102 (1985) 164-168
6. Lee C.T., Guo H.R., and Chen J.B. Hyponatremia in the emergency department. Am J Emerg Med 18 (2000) 264-268
7. Bennani S.L., Abouqal R., Zeggwagh A.A., et al. [Incidence, causes and prognostic factors of hyponatremia in intensive care]. Rev Med Interne 24 (2003) 224-229
8. Terzian C., Frye E.B., and Piotrowski Z.H. Admission hyponatremia in the elderly. Factors influencing prognosis. J Gen Intern Med 9 (1994) 89-91
9. Arieff A.I., Llach F., and Massry S.G. Neurological manifestations and morbidity of hyponatremia. Correlation with brain water and electrolytes. Medicine (Baltimore) 55 (1976) 121-129
10. Goldberg A., Hammerman H., Petcherski S., et al. Prognostic importance of hyponatremia in acute ST-elevation myocardial infarction. Am J Med 117 (2004) 242-248
11. Ruf A.E., Kremers W.K., Chavez L.L., Descalzi V.I., Podesta L.G., and Villamil F.G. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 11 (2005) 336-343
12. Borroni G., Maggi A., Sangiovanni A., Cazzaniga M., and Salerno F. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig Liver Dis 32 (2000) 605-610
13. Baylis P.H. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 35 (2003) 1495-1499
14. Verbalis J.G. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 17 (2003) 471-503
15. Davison J.M., Vallotton M.B., and Lindheimer M.D. Plasma osmolality and urinary concentration and dilution during and after pregnancy. Evidence that lateral recumbency inhibits maximal urinary concentrating ability. Br J Obstet Gynaecol 88 (1981) 472-479
16. Ishikawa S.E., and Schrier R.W. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol 58 (2003) 1-17
17. Robinson A.G., Roberts M.M., Evron W.A., Verbalis J.G., and Sherman T.G. Hyponatremia in rats induces downregulation of vasopressin synthesis. J Clin Invest 86 (1990) 1023-1029
18. Robertson G.L. Physiology of ADH secretion. Kidney Int Suppl 21 (1987) S20-S26
19. Dunn F.L., Brennan T.J., Nelson A.E., and Robertson G.L. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 52 (1973) 3212-3219
20. Luckey A.E., and Parsa C.J. Fluid and electrolytes in the aged. Arch Surg 138 (2003) 1055-1060
21. Andreoli T.E. Water. Normal balance, hyponatremia, and hypernatremia. Ren Fail 22 (2000) 711-735
22. Fried L.F., and Palevsky P.M. Hyponatremia and hypernatremia. Med Clin North Am 81 (1997) 585-609
23. Robinson A.G. Disorders of antidiuretic hormone secretion. Clin Endocrinol Metab 14 (1985) 55-88
24. Robertson G.L., Shelton R.L., and Athar S. The osmoregulation of vasopressin. Kidney Int 10 (1976) 25-37
25. Baylis P.H. Osmoregulation and control of vasopressin secretion in healthy humans. Am J Physiol 253 (1987) R671-R678
26. Goldsmith S.R., Francis G.S., Cowley Jr. A.W., Goldenberg I.F., and Cohn J.N. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 8 (1986) 779-783
27. Baylis P.H. Regulation of vasopressin secretion. Baillieres Clin Endocrinol Metab 3 (1989) 313-330
28. Sladek C.D. Regulation of vasopressin release by neurotransmitters, neuropeptides and osmotic stimuli. Prog Brain Res 60 (1983) 71-90
29. Thibonnier M., Coles P., Thibonnier A., and Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 41 (2001) 175-202
30. Lee C.R., Watkins M.L., Patterson J.H., et al. Vasopressin. A new target for the treatment of heart failure. Am Heart J 146 (2003) 9-18
31. Costello-Boerrigter L.C., Boerrigter G., and Burnett Jr. J.C. Revisiting salt and water retention. New diuretics, aquaretics, and natriuretics. Med Clin North Am 87 (2003) 475-491
32. Skott O. Body sodium and volume homeostasis. Am J Physiol Regul Integr Comp Physiol 285 (2003) R14-R18
33. Thunhorst R.L., and Johnson A.K. Effects of hypotension and fluid depletion on central angiotensin-induced thirst and salt appetite. Am J Physiol Regul Integr Comp Physiol 281 (2001) R1726-R1733
34. Striker E.M., Callahan J.B., Huang W., and Sved A.F. Early osmoregulatory stimulation of neurohypophysial hormone secretion and thirst after gastric NaCl loads. Am J Physiol Regul Integr Comp Physiol 282 (2002) R1710-R1717
35. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001) 2417-2423
36. Cardenas A., and Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab 17 (2003) 607-622
37. Gines P., Berl T., Bernardi M., et al. Hyponatremia in cirrhosis. From pathogenesis to treatment. Hepatology 28 (1998) 851-864
38. Anderson R.J., Berl T., McDonald K.D., and Schrier R.W. Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney. J Clin Invest 56 (1975) 420-426
39. Breyer M.D., Jacobson H.R., and Hebert R.L. Cellular mechanisms of prostaglandin E2 and vasopressin interactions in the collecting duct. Kidney Int 38 (1990) 618-624
40. Zerbe R., Stropes L., and Robertson G. Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med 31 (1980) 315-327
41. Bartter F.C., and Schwartz W.B. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 42 (1967) 790-806
42. Fraser C.L., and Arieff A.I. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 102 (1997) 67-77
43. Beck L.H. The aging kidney. Defending a delicate balance of fluid and electrolytes. Geriatrics 55 (2000) 26-28, 31-22
44. Phillips P.A., Rolls B.J., Ledingham J.G.G., et al. Reduced thirst after water deprivation in healthy elderly men. N Engl J Med 311 (1984) 753-759
45. Mulkerrin E., Epstein F.H., and Clark B.A. Aldosterone responses to hyperkalemia in healthy elderly humans. J Am Soc Nephrol 6 (1995) 1459-1462
46. Miller P.D., Linas S.L., and Schrier R.W. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 243 (1980) 2513-2515
47. 1B receptor ligands. Prog Brain Res 139 (2002) 197-210
48. Gerbes A.L., Gulberg V., Gines P., et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist. A randomized double-blind multicenter trial. Gastroenterology 124 (2003) 933-939
49. Wong F., Blei A.T., Blendis L.M., and Thuluvath P.J. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia. A multicenter, randomized, placebo-controlled trial. Hepatology 37 (2003) 182-191
50. 2-receptor blockade with tolvaptan in patients with chronic heart failure. Results from a double-blind, randomized trial. Circulation 107 (2003) 2690-2696
51. Gheorghiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. A randomized controlled trial. JAMA 291 (2004) 1963-1971
52. 2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia. J Am Soc Nephrol 15 (2004) 356A (abstr SA-P0254)
53. Mallie J.P., Bichet D.G., and Halperin M.L. Effective water clearance and tonicity balance. The excretion of water revisited. Clin Invest Med 20 (1997) 16-24
54. 2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia. J Am Soc Nephrol 15 (2004) 355A (abstr SA-P0251)
55. 2 antagonist, increased serum sodium and effective water clearance in patients with euvolemic or hypervolemic hyponatremia. J Am Soc Nephrol 15 (2004) 355A (abstr SA-P0243)